永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

佛诞节休市 05-02 16:08:25

3.950

-0.120

-2.95%

最高4.100	最低3.930	成交量6.00万
今开4.100	昨收4.070	日振幅4.18%
总市值20.33亿	流通市值20.33亿	总股本5.15亿
成交额24.06万	换手率0.01%	流通股本5.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":3.95,"timestamp":1746173305037,"preClose":4.07,"halted":0,"volume":60000,"delay":0,"floatShares":514584000,"shares":514584000,"eps":-0.3909596493610162,"marketStatus":"佛诞节休市","change":-0.12,"latestTime":"05-02 16:08:25","open":4.1,"high":4.1,"low":3.93,"amount":240550,"amplitude":0.041769,"askPrice":3.95,"askSize":1000,"bidPrice":3.91,"bidSize":8000,"shortable":0,"etf":0,"ttmEps":-0.3909596493610162,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":4.07,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.38709677394380854,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/wiki","defaultTab":"wiki","newsList":[{"id":"2532868288","title":"叮当健康：旗下药房上架礼来阿尔茨海默病创新药记能达®","url":"https://stock-news.laohu8.com/highlight/detail?id=2532868288","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532868288?lang=zh_cn&edition=full","pubTime":"2025-05-02 11:31","pubTimestamp":1746156714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0689472784.USD","LU0203201768.USD","LU0708995401.HKD","LU0354030511.USD","LU0114720955.EUR","LLY","LU0203202063.USD","LU0238689110.USD","LU0471298777.SGD","LU1035775433.USD","LU1989771016.USD","LU0058720904.USD","IE00BK4W5M84.HKD","IE00BJT1NW94.SGD","LU0096364046.USD","09886","SG9999015978.USD","LU2237443465.HKD","LU2471134796.USD","SG9999014914.USD","LU2602419157.SGD","LU0943347566.SGD","LU2491050071.SGD","LU1623119135.USD","BK4007","LU2491049909.HKD","LU0106261372.USD","LU0354030438.USD","LU0006306889.USD","LU0640476718.USD","SGXZ57979304.SGD","LU2552382132.HKD","LU0820561818.USD","LU1057294990.SGD","LU2552382215.SGD","SG9999015945.SGD","SG9999001176.SGD","LU0256863902.USD","06978","BK4599","159992","LU1280957306.USD","MCI","LU1064131342.USD","IE0002141913.USD","LU2237443382.USD","LU2360106947.USD","SGXZ99366536.SGD","LU0094547139.USD","LU2471134523.USD"],"gpt_icon":0},{"id":"2531702177","title":"阳光诺和：公司将要收购的朗研生命将采取仿制药与创新药协同发展的模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702177","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531702177?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:52","pubTimestamp":1746003148,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司将要收购的标的朗研投资目前是以生产仿制药为主，将来是像恒瑞一样向生产创新药为主转型还是继续以生产仿制药为主？阳光诺和回复：尊敬的投资者，您好！公司将要收购的朗研生命将采取仿制药与创新药协同发展的模式。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0216","688621","BK1574","159992","BK1161"],"gpt_icon":0},{"id":"2531706228","title":"永泰生物-B盘中异动 临近收盘股价大涨5.96%报4.090港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531706228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531706228?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:59","pubTimestamp":1745999985,"startTime":"0","endTime":"0","summary":"2025年04月30日临近收盘15时59分，永泰生物-B股票出现波动，股价大幅拉升5.96%。截至发稿，该股报4.090港元/股，成交量4.9万股，换手率0.01%，振幅5.44%。资金方面，该股资金流入13.433万港元，流出2.33万港元。永泰生物-B股票所在的生物技术行业中，整体涨幅为1.27%。其相关个股中，康希诺生物、乐普生物-B、帝王国际投资涨幅较大，振幅较大的相关个股有康希诺生物、乐普生物-B、绿竹生物-B，振幅分别为13.32%、12.39%、10.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430155945974b4625&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430155945974b4625&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2531705837","title":"4月港股创新药ETF领涨，A500ETF基金(512050)蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2531705837","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531705837?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:38","pubTimestamp":1745998714,"startTime":"0","endTime":"0","summary":"2025年“全球视野·下注中国”十大核心ETF最新解读（月报）","market":"us","thumbnail":"https://img3.gelonghui.com/a927f-5e2c1b5a-423e-4ab5-b697-385d982604df.jpg?guru_height=703&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a927f-5e2c1b5a-423e-4ab5-b697-385d982604df.jpg?guru_height=703&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2122074","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","159928","512050","510900","513120","513500","BK1161","BK1574","588200","159593","159792","159949"],"gpt_icon":0},{"id":"2531406705","title":"研究结果亮相国际会议！东阳光药2款创新药临床前研究登陆2025 AACR年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2531406705","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531406705?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:36","pubTimestamp":1745998583,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年4月25日至30日，备受瞩目的第116届美国癌症研究协会年会在美国芝加哥盛大召开。东阳光药2款创新药——靶向LY6G6D阳性肿瘤细胞和免疫细胞表面激活型共刺激分子双特异性抗体HEC-921、pan KRAS抑制剂HEC211909的临床前研究亮相本次会议，旨在加速推动临床转化和全球合作，彰显公司研发实力获得国际同行认可!相较于HRAS和NRAS，HEC211909对KRAS表现出高度选择性。临床前显示具有良好的药代动力学特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01558","BK0070","600673","BK0012","06978","BK1515","BK0003","BK0028","BK1191","BK0188","BK0265","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531735757?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0012","LU2328871848.SGD","BK0060","BK0188","LU1328615791.USD","ONC","BK0187","BK0209","BK4139","06160","LU1969619763.USD","688235","LU1064131003.USD","LU0588546209.SGD","688382","BK0183","LU2148510915.USD","09969","BK1583","BK0132","002422","000963","159992","LU0405327494.USD","LU0405327148.USD","BK1500","06978","LU0307460666.USD","LU1064130708.USD","399300","688266","BK1588","BK1161","LU2488822045.USD","688428","BK0028","159982","600276","BK1574","BK0239","BK0196","BK0175"],"gpt_icon":0},{"id":"2531972824","title":"百济神州美国专利纠纷胜诉，创新药沪深港ETF涨超1%，创新药龙头拐点或现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2531972824","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531972824?lang=zh_cn&edition=full","pubTime":"2025-04-30 10:13","pubTimestamp":1745979209,"startTime":"0","endTime":"0","summary":"消息面，百济神州2025年4月30日公告称，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到公司质疑的第11,672,803号美国专利的全部权利无效。受利好刺激，创新药板块盘初拉升，相关ETF——创新药沪深港ETF涨超1%，年初至今涨近14%。相关机构表示，百济神州获胜意味着中国创新药国际化之路取得了阶段性胜利，这也是真正成为具有国际竞争力的MNC的必经过程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430101941974ae642&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK1574","06160","BK1583","BK1161","LU0588546209.SGD","06978","LU0307460666.USD","LU2328871848.SGD","ONC","LU1969619763.USD","BK1588","BK1500"],"gpt_icon":0},{"id":"2531400737","title":"港股创新药板块盘初拉升，百济神州涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531400737","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531400737?lang=zh_cn&edition=full","pubTime":"2025-04-30 09:48","pubTimestamp":1745977688,"startTime":"0","endTime":"0","summary":"南方财经4月30日电，港股创新药板块盘初拉升，百济神州涨超6%，石药集团、荣昌生物涨超3%，泰格医药、白云山、君实生物跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394091766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU2328871848.SGD","06160","BK1588","BK1161","BK4614","LU0588546209.SGD","LU1969619763.USD","BK1500","HSTECH","06978","LU0307460666.USD","BK1574","YANG","HSCEI","ONC","BK1583"],"gpt_icon":0},{"id":"2531774574","title":"【银河证券：医药行情将迎来持续性修复 看好创新药产业链在今年持续良好表现】 中国银河证券研报表示，医药板块经历较长时间调整，整体估值处于较低水平，且公募持仓低配，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药械有望获益。银河证券认为医药行情将迎来持续性修复，结构性机会依然存在，从短期和中长期确定性增长角度来选择标的，看好创新药产业链在今年持续良好表现。建议关注人工智能技术导入促进设备智能化、诊断服务、体检服务等领域新场景应用的快速推进，进而对于板块带来的持续性估值提升机会。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774574","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531774574?lang=zh_cn&edition=full","pubTime":"2025-04-30 08:42","pubTimestamp":1745973765,"startTime":"0","endTime":"0","summary":"中国银河证券研报表示，医药板块经历较长时间调整，整体估值处于较低水平，且公募持仓低配，2025年在支持引导商保发展的政策背景下，支付端有望边际改善，创新药械有望获益。银河证券认为医药行情将迎来持续性修复，结构性机会依然存在，从短期和中长期确定性增长角度来选择标的，看好创新药产业链在今年持续良好表现。建议关注人工智能技术导入促进设备智能化、诊断服务、体检服务等领域新场景应用的快速推进，进而对于板块带来的持续性估值提升机会。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/30084250027763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161027","399265","601881","BK0188","09939","161631","BK1147","BK1564","BK1574","159938","06881","06978","BK1515","BK0276","BK1161","159992"],"gpt_icon":0},{"id":"2531745124","title":"银河证券：看好创新药产业链在今年持续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2531745124","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531745124?lang=zh_cn&edition=full","pubTime":"2025-04-30 08:41","pubTimestamp":1745973678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09939","BK0276","161027","399265","159992","BK1574","BK0188","159938","06881","06978","161631","601881","BK1515","BK1564","BK1161","BK1147"],"gpt_icon":0},{"id":"2531123997","title":"创新药迎来收获期 上市药企加速出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2531123997","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531123997?lang=zh_cn&edition=full","pubTime":"2025-04-30 06:59","pubTimestamp":1745967582,"startTime":"0","endTime":"0","summary":"报告期内，百利天恒收到其核心产品BL-B01D1的海外合作伙伴百时美施贵宝基于合作协议支付的8亿美元首付款，成为创新药出海拉动业绩增长的典范。医药板块市值最高的恒瑞医药，去年营收279.85亿元，同比增长22.63%，实现归母净利润63.37亿元，同比增长47.27%。2024年，恒瑞医药创新药收入138.92亿元，同比增长30.6%；对外许可收入约超2.73亿美元。在国内竞争环境整体加剧之下，医药企业加速出海进程，并迎来收获期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30065950025273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2531774201","title":"重磅解读！","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774201","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531774201?lang=zh_cn&edition=full","pubTime":"2025-04-29 16:19","pubTimestamp":1745914740,"startTime":"0","endTime":"0","summary":"五大基金经理解读《医药工业数智化转型实施方案》中国基金报记者方丽曹雯璟近日，工信部等七部门印发《医药工业数智化转型实施方案》，《实施方案》提出了两个阶段的发展目标。最后，通过数智化监管手段，可以更好地保障药品质量安全，维护人民生命健康。年初以来地缘政治风险带来的不确定性增加，我们预计会加速相关细分领域的进口替代进程，因此可重点关注这","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656266272&idx=2&sn=91f0ba185fc2feb54dc7be286af70209&chksm=8a8e7b26af13c89c3622949b114225444fe022f45a3729acffefd451d1a663f051bad4a55a51&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656266272&idx=2&sn=91f0ba185fc2feb54dc7be286af70209&chksm=8a8e7b26af13c89c3622949b114225444fe022f45a3729acffefd451d1a663f051bad4a55a51&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09939","06978","BK1161","BK1515"],"gpt_icon":0},{"id":"2531123732","title":"创新药概念异动 凯莱英涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531123732","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531123732?lang=zh_cn&edition=full","pubTime":"2025-04-29 10:12","pubTimestamp":1745892720,"startTime":"0","endTime":"0","summary":"人民财讯4月29日电，创新药概念异动，ST香雪涨超8%，泓博医药、凯莱英涨超7%，药明康德、汉商集团、九州通涨超4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910120094e6bb84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042910120094e6bb84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","06821","BK1191","BK1574","BK1161"],"gpt_icon":0},{"id":"2531126152","title":"港股创新药板块盘初走高，泰凌医药涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531126152","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531126152?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:59","pubTimestamp":1745891997,"startTime":"0","endTime":"0","summary":"南方财经4月29日电，港股创新药板块盘初走高，泰凌医药涨近7%，石药集团涨超4%，百济神州、昭衍新药、药明生物纷纷上涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293392489119.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSCEI","01011","BK1191","BK4614","YANG","BK1161","HSTECH","06978","BK1574"],"gpt_icon":0},{"id":"2531821605","title":"港股创新药板块盘初走高，泰凌医药(01011.HK)涨近7%，石药集团(01093.HK)涨超4%，百济神州(06160","url":"https://stock-news.laohu8.com/highlight/detail?id=2531821605","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531821605?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:49","pubTimestamp":1745891393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0516423091.SGD","LU0823426308.USD","LU0708995583.HKD","603127","06978","LU2328871848.SGD","BK1610","LU0051755006.USD","LU0819121731.USD","LU0823426480.USD","LU0417516738.SGD","HSTECH","BK1141","LU1226287529.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU1880383366.USD","01093","IE0008369823.USD","159992","BK1576","HSCEI","01011","LU1688375341.USD","BK4614","LU1720050803.USD","BK1588","LU1152091754.HKD","YANG","06127","688235","SG9999004220.SGD","LU1008478684.HKD","06160","02269","LU0359201612.USD","BK1161","IE00B031HY20.USD","LU0588546209.SGD","LU0140636845.USD","IE00BZ08YR35.GBP","LU0456846285.SGD","LU1226287792.SGD","LU0348825331.USD","LU1226288253.USD","07226","BK1583","LU1960683339.HKD","ONC","LU0856984785.SGD"],"gpt_icon":0},{"id":"2531219315","title":"全球创新药投融资环境有所复苏，港股生物技术板块集体大涨，药明康德早盘涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531219315","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531219315?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:48","pubTimestamp":1745891280,"startTime":"0","endTime":"0","summary":"　　4月29日消息，港股生物技术板块多股大涨，截至发稿，药明康德、科伦博泰生物涨近6%，创胜集团、来凯医药、乐普生物涨超5%，云顶新耀、中国抗体、康方生物涨超4%。　　消息面上，国投证券发布研报称，全球创新药投融资环境有所复苏，多肽、ADC等细分领域创新研发蓬勃兴起，加速推动CXO行业景气度上行，研发生产外包需求有望逐步改善。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-04-29/doc-ineuuwaf5333570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245177.USD","02359","LU0052750758.USD","LU0708995583.HKD","BK0216","06978","LU2045819591.USD","HSTECH","BK1141","603259","159992","BK1576","HSCEI","LU0456842615.SGD","LU1997245094.SGD","BK4614","YANG","LU2495084118.USD","LU2488822045.USD","LU2242644610.SGD","BK1161","LU1046422090.SGD","BK1574","BK1583","LU2125910500.SGD","LU1997244956.HKD","LU0320764599.SGD"],"gpt_icon":1},{"id":"2530235209","title":"美股异动 | 百济神州(ONC.US)涨逾2% 机构：中国内地创新药出海不受关税影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2530235209","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530235209?lang=zh_cn&edition=full","pubTime":"2025-04-28 23:15","pubTimestamp":1745853341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，百济神州(ONC.US)涨逾2%，报251.10美元。招银国际认为，跨国公司(MNC)购买中国内地创新药资产的热情不减，将持续成为中国内地创新药出海的重要动力。受到关税等地缘政治因素影响，以及集采的逐步推进，国产替代将加速演进，利好国产设备龙头厂商。此外，中国内地创新药出海主要途径为授权出海模式，并不涉及实际产品出口，因此不受关税影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","06978","159992","BK1588","BK1161","LU0588546209.SGD","688235","LU1969619763.USD","BK1574","BK1583","ONC","06160","BK4139","LU0307460666.USD","LU2328871848.SGD","BK0239"],"gpt_icon":0},{"id":"2530442289","title":"永泰生物-B盘中异动 下午盘急速跳水5.78%报3.910港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530442289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530442289?lang=zh_cn&edition=full","pubTime":"2025-04-28 15:29","pubTimestamp":1745825362,"startTime":"0","endTime":"0","summary":"2025年04月28日下午盘15时29分，永泰生物-B股票出现异动，股价大幅下跌5.78%。截至发稿，该股报3.910港元/股，成交量18.6万股，换手率0.04%，振幅5.06%。资金方面，该股资金流入6.071万港元，流出67.603万港元。永泰生物-B股票所在的生物技术行业中，整体跌幅为0.51%。其相关个股中，君实生物、科笛-B、中国抗体-B涨幅较大，振幅较大的相关个股有云康集团、君实生物、中国抗体-B，振幅分别为16.05%、13.75%、13.74%。该公司主要在中国境内开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428152922aa2c7ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428152922aa2c7ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2530419381","title":"医药行业快评：ASCO年会标题发布，多项国产创新药成果入选口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2530419381","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530419381?lang=zh_cn&edition=full","pubTime":"2025-04-28 11:58","pubTimestamp":1745812680,"startTime":"0","endTime":"0","summary":"2025ASCO年会即将举行，多项国产创新药成果入选口头报告，包括信达生物、科伦博泰等多个公司的创新药物。国产创新药在全球范围内越来越占优势，建议关注具备高质量创新能力的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042812053794e557c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042812053794e557c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1574","LU2328871848.SGD","LU2488822045.USD","BK1161","BK1583","06978","01801","BK1589"],"gpt_icon":0},{"id":"2530909604","title":"A股创新药概念股震荡走强，博瑞医药涨超10%，创4年新高，艾迪药业、康辰药业涨超6%，诺思兰德、百利天恒、荣昌生物、君实","url":"https://stock-news.laohu8.com/highlight/detail?id=2530909604","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530909604?lang=zh_cn&edition=full","pubTime":"2025-04-28 11:06","pubTimestamp":1745809591,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","688506","LU1969619763.USD","399300","688488","688331","BK0262","BK1161","LU2148510915.USD","LU2328871848.SGD","BK1574","688166","LU1064130708.USD","06978","159982","603590","688180","159992","01877","LU1064131003.USD","BK1583","BK1515","09995"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0482},{"period":"1month","weight":-0.0075},{"period":"3month","weight":0.4416},{"period":"6month","weight":1.0256},{"period":"1year","weight":0.1618},{"period":"ytd","weight":0.7174}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0301},{"period":"3month","weight":0.1127},{"period":"6month","weight":0.0974},{"period":"1year","weight":0.236},{"period":"ytd","weight":0.1219}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。其主要产品是EAL、CAR-T细胞系列及TCR-T细胞系列产品。EAL是一种多靶点细胞免疫治疗产品。它还提供细胞冻存服务。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":0.008334},{"month":6,"riseRate":1,"avgChangeRate":0.116747},{"month":7,"riseRate":0,"avgChangeRate":-0.121182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.037653},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026649},{"month":10,"riseRate":0.6,"avgChangeRate":0.001262},{"month":11,"riseRate":0.6,"avgChangeRate":0.007893},{"month":12,"riseRate":0.8,"avgChangeRate":0.087803}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}